Once weekly alendronate

Drugs of Today

Volumn 39, Issue 5, 2003, Pages 339-346

  Sambrook, Philip ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; RISEDRONIC ACID;

BONE DENSITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DUODENUM INJURY; EROSION; ESOPHAGUS INJURY; FRACTURE; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE;

EID: 0038037244     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.5.799457     Document Type: Review

References (24)

1. Bone, H.G., Adami, S., Rizzoli, R. et al. Weekly administration of alendronate: Rationale and plan for clinical assessment. Clin Therap 2000, 22: 15-28.
2. Lin, J.H., Duggan, D.E., Chen, I.W., Ellsworth, R.L. Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals. Drug Metab Disps 1991, 19: 926-32.
3. Porras, A.G., Holland, S.D., Gertz, B.J. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36: 315-28.
4. Roschger, P., Rinnerthaler, S., Yates, J., Rodan, G.A., Fratzl, P., Klaushofer, K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29: 185-91.
5. Boivin, G.Y., Chavassieux, P.M., Santora, A.C., Yates, J., Meunier, P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27: 687-94.
6. Porras, A.G., Kline, W., Dilzer, S., Holland, S.D., Freeman, A., Lasseter, K.C. Oral bioavailability of alendronate 35- and 70-mg tablets. Clin Pharmacol Ther 2001, 69: Abstr. P84.
7. Peter, C.P., Kindt, M.V., Majka, J.A. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 1998, 43: 1009-15.
8. Peter, C.P., Handt, L.K., Smith, S.M. Esophageal irritation due to alendronate sodium tablets: Possible mechanisms. Dig Dis Sci 1998, 43: 1998-2002.
9. Balena, R., Toolan, B.C., Shea, M. et al. The effects of two year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92: 2577-86.
10. Schnitzer, T., Bone, H.G., Crepaldi, G. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging 2000, 12: 1-12.
11. Greenspan, S.L., Bone, G., Schnitzer, T.J. et al. Two year results of a once weekly administration of alendronate 70 mg for the treatment of osteoporosis. J Bone Min Res 2002, 17: 1988-96.
12. Hernandez, C.J., Beaupre, G.S., Marcus, R., Carter, D.R. Long term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J Bone Miner Res 2002, 17: 1662-6.
13. Rossini, M., Gatti, D., Girardello, S., Braga, V., James, G., Adami, S. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000, 27: 119-22.
14. Luckey, M., Insogna, K., Gilchrist, N. et al. Therapeutic equivalence of alendronate 35 mg once weekly and 5 mg daily in the prevention of postmenopausal osteoporosis. Osteoporosis Int 2000, 11 (Suppl. 2): Abstr. 566.
15. Body, J.J., Lumen, M.A., Di Romana, S. A simplified therapeutic scheme of alendronate for postmenopausal osteoporosis. Osteoporosis Int 1998, 8 (Suppl. 3): Abstr. P332.
16. Hosking, D., Adami, S., Felsenberg, D. et al. Once weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Osteoporosis Int 2002, 13 (Suppl. 1): Abstr. P47SA.
17. Gordon, M.S., Gordon, M.B. Response of bone mineral density to once-weekly administration of risedronate. Endocrine Practice 2002, 8: 202-7.
18. Lanza, F., Sahba, B., Schwartz, H. et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study. Amer J Gastroenterol 2002, 97: 58-64.
19. De Papp, A.E., Palmisano, J., Sackarowitz, J.T., Geba, G.P. Upper GI tolerability of once-weekly alendronate 70 mg with concomitant NSAID use. Am J Gastroenterol 2002, 97 (Suppl. 9): S52-S53.
20. Greenspan, S., Field-Munves, E., Tonino, R. et al. Tolerability of once weekly alendronate in patients with osteoporosis: A randomised double blind placebo controlled trial. Mayo Clin Proc 2002, 77: 1044-52.
21. Genco, R.J., Van Dyke, T., Leung, A. et al. Two-year gastrointestinal safety and tolerability of alendronate 70 mg once weekly. J Bone Miner Res 2001, 16 (Suppl. 1): Abstr. S528.
22. Kendler, D.L., Diez-Perez, A., Gaines, K.A., Verbruggen, N., Melton, M.E. Patient preference of once weekly or daily administration of alendronate for osteoporosis: A randomized cross-over study. Ann Rheum Dis 2002, 61 (Suppl. 1): Abstr. 50.
23. Palmisano, J., Melton, M., Lewiecki, E.M. et al. Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. Osteoporos Int 2002, 13 (Suppl. 1): Abstr. S36.
24. Cooper, C., Sen, S., Zhang, Q., Finch, E. Persistency with osteoporotic medications in the United Kingdom. Ann Rheum Dis 2002, 61 (Suppl. 1): Abstr. 49.